Literature DB >> 18359921

A note on population analysis of dissolution-absorption models using the inverse Gaussian function.

Jian Wang1, Michael Weiss, David Z D'Argenio.   

Abstract

Because conventional absorption models often fail to describe plasma concentration-time profiles following oral administration, empirical input functions such as the inverse Gaussian function have been successfully used. The purpose of this note is to extend this model by adding a first-order absorption process and to demonstrate the application of population analysis using maximum likelihood estimation via the EM algorithm (implemented in ADAPT 5). In one example, the analysis of bioavailability data of an extended-release formulation, as well as the mean dissolution times estimated in vivo and in vitro with the use of the inverse Gaussian function, is well in accordance, suggesting that the inverse Gaussian function indeed accounts for the in vivo dissolution process. In the other example, the kinetics of trapidil in patients with liver disease, the absorption/dissolution parameters are characterized by a high interindividual variability. Adding a first-order absorption process to the inverse Gaussian function improved the fit in both cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359921      PMCID: PMC2648518          DOI: 10.1177/0091270008315956

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  15 in total

1.  Commentary: using the convection-dispersion model and transit time density functions in the analysis of organ distribution kinetics.

Authors:  M S Roberts; Y G Anissimov; M Weiss
Journal:  J Pharm Sci       Date:  2000-12       Impact factor: 3.534

Review 2.  Pharmacokinetic strategies in deciphering atypical drug absorption profiles.

Authors:  Honghui Zhou
Journal:  J Clin Pharmacol       Date:  2003-03       Impact factor: 3.126

3.  Classification of dissolution profiles in terms of fractional dissolution rate and a novel measure of heterogeneity.

Authors:  Petr Lánský; Michael Weiss
Journal:  J Pharm Sci       Date:  2003-08       Impact factor: 3.534

4.  Pharmacokinetics of trapidil in patients with chronic liver disease.

Authors:  A Berndt; M Looby; K Pönicke; B Zipprich; M Weiss
Journal:  J Clin Pharmacol       Date:  1996-10       Impact factor: 3.126

5.  A novel extravascular input function for the assessment of drug absorption in bioavailability studies.

Authors:  M Weiss
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

6.  Transit time dispersion in pulmonary and systemic circulation: effects of cardiac output and solute diffusivity.

Authors:  Michael Weiss; Tom C Krejcie; Michael J Avram
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-02-24       Impact factor: 4.733

7.  Modelling of initial distribution of drugs following intravenous bolus injection.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Bioavailability of trapidil tablets.

Authors:  M Weiss; W Sziegoleit; K Pönicke; M Schobess; A Fahr; H J Mest
Journal:  Arzneimittelforschung       Date:  1989-09

9.  Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.

Authors:  S D Ferrara; L Tedeschi; G Frison; R Orlando; M Mazzo; R Zordan; R Padrini; P Palatini
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

10.  Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition.

Authors:  Xiaoping Zhang; Keith Nieforth; Jean-Marie Lang; Regine Rouzier-Panis; Jacques Reynes; Albert Dorr; Stanley Kolis; Mark R Stiles; Tosca Kinchelow; Indravadan H Patel
Journal:  Clin Pharmacol Ther       Date:  2002-07       Impact factor: 6.875

View more
  6 in total

1.  Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.

Authors:  Eyob D Adane; Zhiwei Liu; Tian-Xiang Xiang; Bradley D Anderson; Markos Leggas
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

2.  Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model).

Authors:  Jun Shen; Alison Boeckmann; Andrew Vick
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-04       Impact factor: 2.745

3.  Empirical models for fitting of oral concentration time curves with and without an intravenous reference.

Authors:  Michael Weiss
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-01       Impact factor: 2.745

4.  Analysis of Complex Absorption After Multiple Dosing: Application to the Interaction Between the P-glycoprotein Substrate Talinolol and Rifampicin.

Authors:  Michael Weiss; David Z D'Argenio; Werner Siegmund
Journal:  Pharm Res       Date:  2022-09-26       Impact factor: 4.580

5.  A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.

Authors:  Xavier Delavenne; Edouard Ollier; Thierry Basset; Laurent Bertoletti; Sandrine Accassat; Arnauld Garcin; Silvy Laporte; Paul Zufferey; Patrick Mismetti
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

Review 6.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.